Last updated: May 26, 2026
Executive summary: Amphotericin B is a widely sourced antifungal active ingredient used in multiple branded and generic formulations, with supply split across (1) injectable amphotericin B deoxycholate and (2) liposomal amphotericin B products. Supplier ecosystems differ by form because regulatory dossiers, sterile manufacturing capacity, and excipient/lipid supply chains constrain entry. The supplier set also varies by geography and whether the product is marketed under innovator brands or as authorized generics.
Which companies supply amphotericin B deoxycholate injectable (Amphotericin B)
Answer: Amphotericin B deoxycholate injectable supply is dominated by global sterile injectables manufacturers and regional distributors, with most supply packaged as multi-dose vials produced under NDA/ANDA manufacturing authorizations in the US and under marketing authorizations abroad.
Common product configuration
- Sterile lyophilized or reconstitutable powder for IV infusion
- Labeled for systemic fungal infections
- High manufacturing bar because of sterility assurance and control of particle/aggregation characteristics
Typical supplier categories
- Large generic injectables groups with sterile penicillin-amphotericin-class experience
- Contract manufacturing organizations supporting sterile fill-finish (sterile bottling and lyophilization) for amphotericin-based products
- Regional wholesalers that aggregate imports for hospital and government procurement
Supply chain constraints that drive vendor selection
- Lyophilization line availability
- QC release capacity (sterility, endotoxin, potency)
- Managing batch-to-batch variability for colloidal characteristics and reconstitution performance
- Cold-chain needs are less uniform than for lipid formulations, but transport temperature control still matters for sterile stability
Which companies supply liposomal amphotericin B (L-AmB)
Answer: Liposomal amphotericin B supply is concentrated in fewer manufacturers because lipid formulation IP, specialized manufacturing (lipid mixing, size control), and tighter regulatory expectations restrict replication.
Key formulation characteristics that narrow the supplier set
- Phospholipid and cholesterol sourcing
- Particle size distribution and encapsulation efficiency targets
- Sterile, aseptic manufacturing controls for nanoscale dispersion
Why liposomal amphotericin B has different supplier dynamics
- Higher formulation complexity than amphotericin B deoxycholate
- More restricted contract manufacturing partners
- Longer lifecycle with stronger brand-based exclusivity history in many markets
Who makes amphotericin B active pharmaceutical ingredient (API)
Answer: API suppliers for amphotericin B exist across multiple Asian and European chemical and fermentation-derived API manufacturers, but the observable market at the hospital and tender level is usually the finished sterile injectable provider rather than the API brand.
How to think about API-to-finished-product sourcing
- Finished-dose manufacturers typically qualify one or a small set of API suppliers
- API specifications (potency, impurities, particle profile) must align with finished product release targets
- Supplier substitution is possible but requires regulatory and validation work at the drug-product level
What dosage forms and strengths are most commonly sourced
Answer: Most tenders and hospital purchasing focus on:
- Amphotericin B deoxycholate IV infusion (vials; dose delivered after reconstitution)
- Liposomal amphotericin B IV infusion (vials; lipid-based dispersion)
Procurement drivers by form
- Deoxycholate is often the lower-cost option where kidney toxicity mitigation is less constrained
- Liposomal amphotericin B is selected where renal safety profile and tolerability drive formulary decisions
Which regulatory filings determine who can supply amphotericin B in the US
Answer: In the US, supply availability is governed by FDA approval status and manufacturing authorization for the finished sterile injectable product, reflected through:
- NDA approvals for branded products
- ANDA approvals for generics and authorized generics
- Orange Book listings for relevant patents tied to formulation and manufacturing changes
What buyers should check before selecting a supplier
- FDA-approved label and dosing guidance for the specific amphotericin B formulation
- Sterility manufacturing site and current inspection status
- Supply continuity history around shortages
What is the Orange Book status of amphotericin B products
Answer: Orange Book status differs sharply between amphotericin B deoxycholate products and liposomal amphotericin B, because patent estates tend to include formulation, method, and manufacturing/process patents that vary by sponsor.
How Orange Book affects supplier entry
- Patent-protected formulations and processes can delay generic competition
- Paragraph IV filings (where applicable) can force settlements that lock in or delay market entry for a period
What generic entry risks exist for amphotericin B products
Answer: Generic entry risk is highest for products with fewer proprietary formulation constraints and clearer pathway for demonstrating bioequivalence/clinical comparability. Risk is lower where formulation IP, process controls, or stability packaging are tightly protected.
Where supply disruptions occur in practice
- Sterile manufacturing line outages
- Raw material allocation for sterile excipients
- Recall events due to sterility/particulate findings
- Transport damage to vials and lyophilized product cabinets
Which companies are challenging amphotericin B patents via Paragraph IV
Answer: Specific Paragraph IV challengers depend on the Orange Book patent landscape for each labeled product and can vary by sponsor and formulation. The relevant set is defined product-by-product (deoxycholate vs liposomal), not by amphotericin B as a single monograph.
(No actionable listing is provided here because a complete, accurate “who filed what” map requires product-specific Orange Book patent data and litigation records, which are not contained in the input.)
How do amphotericin B supplier choices change by geography
Answer: US purchasing and EU procurement often use different supplier lineups due to:
- Different regulatory approvals for sterile sites
- Distinct packaging and labeling requirements
- Import licensing and tender restrictions in government systems
- Different product availability for liposomal versus deoxycholate presentations
Hospital buying patterns
- US: emphasis on FDA-approved sterile supply with strong lot release documentation
- EU/MENA/APAC: often uses nationally authorized products and tender-based sourcing with regional distributors
How many suppliers can typically cover amphotericin B demand
Answer: Coverage depends on formulation. Deoxycholate has a broader finished-product vendor base because the formulation is more replicable. Liposomal amphotericin B has fewer qualified vendors because the formulation and manufacturing complexity reduces the number of approved substitutes.
Capacity reality for supply planning
- Deoxycholate tends to be more resilient to single-site disruptions, but still faces shortages when sterile fill-finish capacity tightens
- Liposomal supply is more sensitive to lipid excipient availability and the number of qualified sterile nanoscale-manufacturing sites
What manufacturing/IP barriers limit new amphotericin B suppliers
Answer: The limiting factors are less about the basic active substance and more about sterile manufacturing, formulation controls, and regulatory approvals.
Common barriers
- Validated sterile production and aseptic lyophilization capability (deoxycholate)
- Liposome manufacturing controls, particle sizing, and stability testing (liposomal)
- Patent-protected process and formulation changes
- Quality agreement requirements and inspection history for sterile sites
How to compare amphotericin B deoxycholate vs liposomal amphotericin B for supply selection
Answer: The comparison that matters for suppliers is not clinical equivalence. It is regulatory dossier structure, manufacturing complexity, and supply continuity.
| Attribute |
Amphotericin B deoxycholate |
Liposomal amphotericin B |
| Manufacturing complexity |
Lower than liposomal |
Higher (lipid dispersion, size control) |
| Qualified vendor count |
Usually higher |
Usually lower |
| Shortage sensitivity |
Medium |
Higher |
| IP sensitivity |
Moderate |
Often higher due to formulation/process patents |
| Procurement fit |
Broader formularies, lower-cost procurement |
Renal-protection-driven formularies |
Key Takeaways
- Amphotericin B supply splits by formulation: deoxycholate injectable has a broader supplier base; liposomal amphotericin B has fewer qualified vendors.
- Buyer supplier selection is constrained by sterile manufacturing capacity, lot release QC, and formulation/process validation rather than amphotericin B API availability alone.
- Regulatory status and Orange Book-linked patents are product-specific; they drive whether generics can enter and when, shaping vendor count and pricing.
- Supply risk monitoring should be driven by finished-dose sterile site continuity and past shortage/recall signals, especially for liposomal products.
FAQs
- What is the difference in supplier base between amphotericin B deoxycholate and liposomal amphotericin B?
- How do sterile manufacturing site approvals affect amphotericin B availability during shortages?
- What excipient or lipid supply constraints most often impact liposomal amphotericin B production?
- How does Orange Book patent coverage influence generic entry for amphotericin B formulations?
- What documentation should hospitals require from amphotericin B suppliers for procurement and audits?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-05-26)
